Compare Aurora Cannabis Inc (ACB) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Aurora Cannabis Inc vs Thomson Reuters Corp — how do they compare? Aurora Cannabis Inc trades at $2.67 (market cap $165.36M), while Thomson Reuters Corp trades at $89.21 (market cap $39.64B). The key difference: Thomson Reuters Corp is far larger — about 239.7× Aurora Cannabis Inc's market cap, and Thomson Reuters Corp pays a 2.89% dividend while Aurora Cannabis Inc pays none. Which is the better fit depends on your goals.
| ACB | TRI | |
|---|---|---|
Market Cap | $165.36M | $39.64B |
Sector | Health | Industrials |
52-Week High | $6.23 | $214.21 |
52-Week Low | $2.67 | $76.55 |
Enterprise Value | $99.82M | $41.59B |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.
The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.
Thomson Reuters (TRI) trades at $90.76, up 1.74% with bullish technical indicators and strong analyst support. The company reported Q1 2026 EPS of $1.23, beating estimates, while revenue reached $7.48B in 2025. Recent corporate actions include a special dividend and reverse stock split. Technical analysis shows resistance near $92 with RSI indicating potential overbought conditions.
Outlook remains positive with a consensus price target of $129.96, though risks include AI implementation challenges and competitive pressures. Revenue growth is steady, but net income margin compression from 39.66% in 2023 to 20.09% in 2025 warrants monitoring. Institutional sentiment is bullish with 51.85% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aurora Cannabis Inc
Aurora Cannabis, based in Edmonton, Canada, grows and distributes both medical and recreational cannabis under several brands, including Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. While its main market is Canada, the company has also expanded globally through medical cannabis export agreements.
Read more on ACB →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
